The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Fast-acting antidepressants rapidly stimulate ERK signaling and BDNF release in primary neuronal cultures
Open accessAbstract
Recent preclinical and clinical studies demonstrate that three functionally different compounds, the NMDA receptor channel blocker ketamine, mGlu 2/3 receptor antagonist LY341495, and NMDA receptor glycine site agent GLYX-13 produce rapid and long lasting antidepressant effects. Furthermore, these agents are reported to stimulate ERK and mTORC1 signaling in brain. Here we used rat primary cortical culture neurons to further examine the cellular actions of these agents. The results demonstrate that low concentrations of all three compounds rapidly increase levels of the phosphorylated and activated forms of ERK and a downstream target of mTORC1, p70S6 kinase, in a concentration and time dependent manner. In addition, each compound rapidly increases BDNF release into the culture media. Further studies demonstrate that induction of BDNF release, as well as stimulation of phospho-ERK is blocked by incubation with an AMPA receptor antagonist. The requirement for AMPA receptor stimulation suggests that the effects of these rapid agents are activity dependent. This possibility is supported by studies demonstrating that neuronal silencing, via incubation with the GABA A receptor agonist muscimol, completely blocks phospho-ERK and BDNF release by each agent. Finally, incubation with each drug for 24 h increases the number and length of neuronal branches. Together, the results demonstrate that these three different rapid acting antidepressant agents increase ERK signaling and BDNF release in an activity dependent manner that leads to increased neuronal complexity. Further studies will be required to determine the exact mechanisms underlying these effects in cultured neurons and in rodent models.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Unlike traditional monoaminergic antidepressants, which gradually increase BDNF expression, ketamine induces a rapid release of BDNF [73].”
From Variations in BDNF and Their Role in the Neurotrophic Antidepressant Mechanisms of Ketamine and Esketamine: A Review (2024) · cites this paper as [73]
The cited source says what the claim attributes to it.
In the citing paper
“The dissociative ketamine is another substance whose antidepressant effects are suggested to result from enhanced BDNF and synaptic plasticity (107).”
From Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics. (2021) · cites this paper as [107]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,526
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Koretz, D., Merikangas, K. R., Rush, A. J., Walters, E. E., & Wang, P. S. (2003) · JAMA · doi:10.1001/jama.289.23.3095 · Cited by 7,988
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Glutamate Receptor Ion Channels: Structure, Regulation, and Function
Traynelis, S. F., Wollmuth, L. P., McBain, C. J., Menniti, F. S., Vance, K. M., Ogden, K. K., Hansen, K. B., Yuan, H., Myers, S. J., & Dingledine, R. (2010) · Pharmacological Reviews · doi:10.1124/pr.109.002451 · Cited by 3,568
A Neurotrophic Model for Stress-Related Mood Disorders
Duman, R. S., & Monteggia, L. M. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.02.013 · Cited by 3,375
Self-citationmTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881
Self-citationNMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P.-F., Kavalali, E. T., & Monteggia, L. M. (2011) · Nature · doi:10.1038/nature10130 · Cited by 1,926
Moghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793
Research works printed but not linked: 1
- Lepack, 2014, BDNF release is required for the behavioral actions of ketamine, Int. J. Neuropsychopharmacol., 18
Cited by
Sorted by citations
Psychedelics promote structural and functional neural plasticity
Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., Burbach, K. F., Soltanzadeh Zarandi, S., Sood, A., Paddy, M. R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.022 · Cited by 1,207
Cortical GABAergic Dysfunction in Stress and Depression: New Insights for Therapeutic Interventions
Fogaça, M. V., & Duman, R. S. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00087 · Cited by 396
Self-citationGlutamatergic Signaling Along The Microbiota-Gut-Brain Axis
Baj, A., Moro, E., Bistoletti, M., Orlandi, V. T., Crema, F., & Giaroni, C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061482 · Cited by 339
Duman, R. S., Deyama, S., & Fogaça, M. V. (2021) · European Journal of Neuroscience · doi:10.1111/ejn.14630 · Cited by 321
Self-citationde Vos, C. M. H., Mason, N. L., & Kuypers, K. P. C. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.724606 · Cited by 269
Yang, C., Ren, Q., Qu, Y., Zhang, J., Ma, M., Dong, C., & Hashimoto, K. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.05.016 · Cited by 254
Abdallah, C. G., Sanacora, G., Duman, R. S., & Krystal, J. H. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.05.010 · Cited by 219
Self-citationKetamine disinhibits dendrites and enhances calcium signals in prefrontal dendritic spines
Ali, F., Gerhard, D. M., Sweasy, K., Pothula, S., Pittenger, C., Duman, R. S., & Kwan, A. C. (2020) · Nature Communications · doi:10.1038/s41467-019-13809-8 · Cited by 196
Self-citationFukumoto, K., Fogaça, M. V., Liu, R.-J., Duman, C., Kato, T., Li, X.-Y., & Duman, R. S. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1814709116 · Cited by 188
Self-citationNeurotrophic mechanisms underlying the rapid and sustained antidepressant actions of ketamine
Deyama, S., & Duman, R. S. (2020) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2019.172837 · Cited by 186
Self-citationBrain-derived neurotrophic factor and inflammation in depression: Pathogenic partners in crime?
Porter, G. A., & O’Connor, J. C. (2022) · World Journal of Psychiatry · doi:10.5498/wjp.v12.i1.77 · Cited by 188
Mechanisms of ketamine and its metabolites as antidepressants
Hess, E. M., Riggs, L. M., Michaelides, M., & Gould, T. D. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114892 · Cited by 175
Neurobiology of rapid-acting antidepressants: convergent effects on GluA1-synaptic function
Duman, R. S., Shinohara, R., Fogaça, M. V., & Hare, B. D. (2019) · Molecular Psychiatry · doi:10.1038/s41380-019-0400-x · Cited by 157
Self-citationKohtala, S. (2021) · Pharmacological Reports · doi:10.1007/s43440-021-00232-4 · Cited by 155
Molecular Pharmacology and Neurobiology of Rapid-Acting Antidepressants
Gould, T. D., Zarate, C. A., & Thompson, S. M. (2019) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010617-052811 · Cited by 133
Fogaça, M. V., Wu, M., Li, C., Li, X.-Y., Picciotto, M. R., & Duman, R. S. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-00916-y · Cited by 129
Self-citationVGF function in depression and antidepressant efficacy
Jiang, C. S., Lin, W.-J., Sadahiro, M., Labonté, B., Ménard, C., Pfau, M. L., Tamminga, C. A., Turecki, G., Nestler, E. J., Russo, S. J., et al. (2017) · Molecular Psychiatry · doi:10.1038/mp.2017.233 · Cited by 124
Deyama, S., Bang, E., Kato, T., Li, X.-Y., & Duman, R. S. (2019) · Biological Psychiatry · doi:10.1016/j.biopsych.2018.12.014 · Cited by 116
Self-citationGhosal, S., Bang, E., Yue, W., Hare, B. D., Lepack, A. E., Girgenti, M. J., & Duman, R. S. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.06.017 · Cited by 111
Self-citationThe opioid system in depression
Jelen, L. A., Stone, J. M., Young, A. H., & Mehta, M. A. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104800 · Cited by 108
BDNF Release and Signaling Are Required for the Antidepressant Actions of GLYX-13
Kato, T., Fogaça, M. V., Deyama, S., Li, X.-Y., Fukumoto, K., & Duman, R. S. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.220 · Cited by 88
Self-citationKetamine and the Future of Rapid-Acting Antidepressants
Riggs, L. M., & Gould, T. D. (2021) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-072120-014126 · Cited by 87
Zinc in the Monoaminergic Theory of Depression: Its Relationship to Neural Plasticity
Doboszewska, U., Właź, P., Nowak, G., Radziwoń-Zaleska, M., Cui, R., & Młyniec, K. (2017) · Neural Plasticity · doi:10.1155/2017/3682752 · Cited by 90
Fogaça, M. V., Fukumoto, K., Franklin, T., Liu, R.-J., Duman, C. H., Vitolo, O. V., & Duman, R. S. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-019-0501-x · Cited by 82
Self-citationMechanisms Controlling the Expression and Secretion of BDNF
Arévalo, J. C., & Deogracias, R. (2023) · Biomolecules · doi:10.3390/biom13050789 · Cited by 89
mGlu2/3 Receptor Antagonists as Novel Antidepressants
Chaki, S. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.03.008 · Cited by 73
Kang, M. J. Y., Hawken, E., & Vazquez, G. H. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.860882 · Cited by 77
Witkin, J. M., Martin, A. E., Golani, L. K., Xu, N. Z., & Smith, J. L. (2019) · Advances in pharmacology · doi:10.1016/bs.apha.2019.03.002 · Cited by 80
Antidepression action of BDNF requires and is mimicked by Gαi1/3 expression in the hippocampus
Marshall, J. J., Zhou, X., Chen, G., Yang, S., Li, Y., Wang, Y., Zhang, Z.-Q., Jiang, Q., Birnbaumer, L., & Cao, C. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1722493115 · Cited by 75
Rapid Acting Antidepressants in Chronic Stress Models: Molecular and Cellular Mechanisms
Hare, B. D., Ghosal, S., & Duman, R. S. (2017) · Chronic Stress · doi:10.1177/2470547017697317 · Cited by 67
Self-citationAllopregnanolone in mood disorders: Mechanism and therapeutic development
Chen, S., Gao, L., Li, X., & Ye, Y. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105682 · Cited by 71
An update on NMDA antagonists in depression
Pochwat, B., Nowak, G., & Szewczyk, B. (2019) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2019.1643237 · Cited by 67
Miyanishi, H., & Nitta, A. (2021) · Pharmaceuticals · doi:10.3390/ph14090889 · Cited by 57
Jiang, N., Lv, J., Wang, H., Lü, C., Wang, Q., Xia, T., Bao, Y., Li, S., & Liu, X. (2019) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2019.09.007 · Cited by 56
Role of a VGF/BDNF/TrkB Autoregulatory Feedback Loop in Rapid-Acting Antidepressant Efficacy
Jiang, C. S., Lin, W., & Salton, S. R. (2018) · Journal of Molecular Neuroscience · doi:10.1007/s12031-018-1124-0 · Cited by 56
Fukumoto, K., Fogaça, M. V., Liu, R.-J., Duman, C. H., Li, X., Chaki, S., & Duman, R. S. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-0705-0 · Cited by 58
Self-citationRapid-Acting Antidepressants: Mechanistic Insights and Future Directions
Gerhard, D. M., & Duman, R. S. (2018) · Current Behavioral Neuroscience Reports · doi:10.1007/s40473-018-0139-8 · Cited by 52
Self-citationBDNF receptor TrkB as the mediator of the antidepressant drug action
Casarotto, P. C., Umemori, J., & Ċastrén, E. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.1032224 · Cited by 53
Yu, H., Lv, D., Shen, M., Zhang, Y., Zhou, D., Chen, Z., & Wang, C. (2018) · Psychiatry Research · doi:10.1016/j.psychres.2018.12.015 · Cited by 51
Inhibition of a Descending Prefrontal Circuit Prevents Ketamine-Induced Stress Resilience in Females
Dolzani, S. D., Baratta, M. V., Moss, J. R., Leslie, N. L., Tilden, S. G., Sørensen, A. T., Watkins, L. R., Lin, Y., & Maier, S. F. (2018) · eNeuro · doi:10.1523/eneuro.0025-18.2018 · Cited by 52
Targeting metaplasticity mechanisms to promote sustained antidepressant actions
Brown, K. A., & Gould, T. D. (2024) · Molecular Psychiatry · doi:10.1038/s41380-023-02397-1 · Cited by 49
KATO, T., & Duman, R. S. (2019) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2019.172827 · Cited by 49
Self-citationPardossi, S., Fagiolini, A., & Cuomo, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252313098 · Cited by 51
Rantamäki, T., & Kohtala, S. (2020) · Pharmacological Reviews · doi:10.1124/pr.119.018697 · Cited by 45
Kohtala, S., Alitalo, O., Rosenholm, M., Rozov, S. V., & Rantamäki, T. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107741 · Cited by 47
Wang, Y., Zhang, N., Liu, L., Jiang, H., Hu, D., Wang, Z., Chen, N., & Zhang, Y. (2022) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2022.01.024 · Cited by 50
Deyama, S., & Kaneda, K. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109335 · Cited by 46
Agnorelli, C., Spriggs, M. J., Godfrey, K., Sawicka, G., Bohl, B., Douglass, H. M., Fagiolini, A. M., Parastoo, H., Carhart-Harris, R. L., Nutt, D. J., et al. (2025) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2025.106132 · Cited by 65
TrkB neurotrophin receptor at the core of antidepressant effects, but how?
Rantamäki, T. (2019) · Cell and Tissue Research · doi:10.1007/s00441-018-02985-6 · Cited by 45
Witkin, J. M., Knutson, D. E., Rodriguez, G. J., & Shi, S. X.-Y. (2018) · Current Pharmaceutical Design · doi:10.2174/1381612824666180730104707 · Cited by 45
Pałucha-Poniewiera, A., Podkowa, K., & Rafało-Ulińska, A. (2021) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.110239 · Cited by 45
Antidepressant mechanisms of ketamine: Focus on GABAergic inhibition
Lüscher, B., Feng, M., & Jefferson, S. J. (2020) · Advances in pharmacology · doi:10.1016/bs.apha.2020.03.002 · Cited by 41
Stress inoculation in mice induces global resilience
Ayash, S., Schmitt, U., Lyons, D. M., & Müller, M. B. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-00889-0 · Cited by 42
Yu, H., Li, M., Zhou, D., Lv, D., Liao, Q., Lou, Z., Shen, M., Wang, Z., Li, M., Xiao, X., et al. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.12.028 · Cited by 41
Novel Targets to Treat Depression: Opioid-Based Therapeutics
Browne, C. A., Jacobson, M. L., & Lucki, I. (2020) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000242 · Cited by 39
Hyperforin Potentiates Antidepressant-Like Activity of Lanicemine in Mice
Pochwat, B., Szewczyk, B., Kotarska, K., Rafało-Ulińska, A., Siwiec, M., Sowa, J. E., Tokarski, K., Siwek, A., Bouron, A., Friedland, K., et al. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00456 · Cited by 38
Śniecikowska, J., Głuch‐Lutwin, M., Bucki, A., Więckowska, A., Siwek, A., Jastrzębska‐Więsek, M., Partyka, A., Wilczyńska, D., Pytka, K., Pociecha, K., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00062 · Cited by 36
Pan, F., Mou, T., Shao, J., Chen, H., Tao, S., Wang, L., Jiang, C., Zhao, M., Wang, Z., Hu, S., et al. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.11.059 · Cited by 35
van Calker, D., Serchov, T., Normann, C., & Biber, K. P. H. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2018.03.014 · Cited by 35
Chuang, H.-W., Wang, T.-Y., Huang, C., & Wei, I. (2022) · Chinese Medicine · doi:10.1186/s13020-021-00549-5 · Cited by 36
Witkin, J. M. (2020) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2020.172854 · Cited by 36
Depoortère, R., Papp, M., Gruca, P., Łasoń, M., Niemczyk, M., Varney, M. A., & Newman‐Tancredi, A. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119860666 · Cited by 35
Molecular and cellular dissection of NMDA receptor subtypes as antidepressant targets
Lang, E., Mallien, A. S., Vasilescu, A.-N., Hefter, D., Luoni, A., Riva, M. A., Borgwardt, S., Sprengel, R., Lang, U. E., Gass, P., et al. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.08.012 · Cited by 33
Pochwat, B., Rafało-Ulińska, A., Domin, H., Misztak, P., Nowak, G., & Szewczyk, B. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.08.006 · Cited by 30
mTOR Knockdown in the Infralimbic Cortex Evokes A Depressive-like State in Mouse
Garro-Martínez, E., Fullana, M. N., Florensa-Zanuy, E., Senserrich, J., Paz, V., Ruiz‐Bronchal, E., Adell, A., Castro, E., Díaz, Á., Pazos, Á., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168671 · Cited by 31
Tricklebank, M. D., Robbins, T. W., Simmons, C., & Wong, E. H. F. (2021) · Psychopharmacology · doi:10.1007/s00213-021-05787-x · Cited by 30
Antidepressants and type 2 diabetes: highways to knowns and unknowns
Alruwaili, N. S., Al-Kuraishy, H. M., Al-Gareeb, A. I., Albuhadily, A. K., Ragab, A. E., Alenazi, A. A., Alexiou, A. T., Papadakis, M., & Batiha, G. E. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01149-z · Cited by 36
Rapastinel - an investigational NMDA-R modulator for major depressive disorder: evidence to date
Ragguett, R.-M., Rong, C., Kratiuk, K., & McIntyre, R. S. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1559295 · Cited by 30
Rafało-Ulińska, A., Brański, P., & Pałucha-Poniewiera, A. (2022) · Pharmaceuticals · doi:10.3390/ph15020125 · Cited by 29
Zhou, D., Zhang, Z., Liu, L., Li, C., Li, M., Yu, H., Cai, X., Sun, X., Shen, X., Wang, J., et al. (2017) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2017.02.004 · Cited by 28
Śniecikowska, J., Newman‐Tancredi, A., & Kołaczkowski, M. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190911122040 · Cited by 31
Is Adult Hippocampal Neurogenesis Really Relevant for the Treatment of Psychiatric Disorders?
Carli, M., Aringhieri, S., Kolachalam, S., Longoni, B., Grenno, G., Rossi, M., Gemignani, A., Fornai, F., Maggio, R., & Scarselli, M. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200818194948 · Cited by 29
Fogaça, M. V., Wu, M., Li, C., Li, X., Duman, R. S., & Picciotto, M. R. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01583-7 · Cited by 28
Self-citationHare, B. D., Pothula, S., Dileone, R., & Duman, R. S. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.107947 · Cited by 26
Self-citationKetamine treatment for anhedonia in unipolar and bipolar depression: a systematic review
Kwaśny, A., Kwaśna, J., Wilkowska, A., Szarmach, J., Słupski, J., Włodarczyk, A., & Cubała, W. J. (2024) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2024.04.014 · Cited by 27
Ali, F., Shao, L.-X., Gerhard, D. M., Sweasy, K., Pothula, S., Pittenger, C., Duman, R. S., & Kwan, A. C. (2020) · Molecular Psychiatry · doi:10.1038/s41380-020-0708-6 · Cited by 25
Self-citationLi, J., Zhang, M., Pei, Y., Yang, Q., Zheng, L., Wang, G., Sun, Y., Yang, W., & Liu, L. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.116723 · Cited by 25
Seo, M. K., Hiền, L. T. T., Park, M. K., Choi, A. J., Seog, D., Kim, S. H., Park, S. W., & Lee, J. G. (2020) · Scientific Reports · doi:10.1038/s41598-020-58017-3 · Cited by 24
KATO, T. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109325 · Cited by 26
Opioid modulation of cognitive impairment in depression
Jacobson, M. L., Wulf, H. A., Browne, C. A., & Lucki, I. (2018) · Progress in brain research · doi:10.1016/bs.pbr.2018.07.007 · Cited by 25
Perisynaptic astrocytes as a potential target for novel antidepressant drugs
Frizzo, M. E., & Ohno, Y. (2020) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2020.11.002 · Cited by 25
Ren, L. (2024) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2023.110910 · Cited by 23
Zemdegs, J., Rainer, Q., Grossmann, C. P., Rousseau-Ralliard, D., Grynberg, A., Ribeiro, E., & Guiard, B. P. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00974 · Cited by 23
Chaki, S., & Watanabe, M. (2023) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-023-01561-6 · Cited by 25
All roads lead to glutamate: NMDA and AMPA receptors as targets for rapid-acting antidepressants
Freudenberg, F., Reif-Leonhard, C., Dawson, G. R., McKernan, R. M., & Reif, A. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107918 · Cited by 23
Chen, F., Li, L., Huang, M., Wang, Y., Wang, L., Jin, F., Yang, L., Gao, M., Li, L., Wang, Y., et al. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.155452 · Cited by 23
The Ketamine Antidepressant Story: New Insights
Alshammari, T. K. (2020) · Molecules · doi:10.3390/molecules25235777 · Cited by 22
Sewell, F. R., Waterson, I., Jones, D., Tricklebank, M. D., & Ragan, I. (2021) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2021.105002 · Cited by 22
Liu, Z., Han, Y., Zhao, H., Luo, W., Jia, L., & Wang, Y. (2019) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2019/3710363 · Cited by 22
Dong, X. Y., Liu, L., Li, Y., Ruan, J., & Wang, H. (2019) · Neurochemical Research · doi:10.1007/s11064-019-02840-2 · Cited by 22
Perković, M. N., Gredičak, M., Šagud, M., Erjavec, G. N., Uzun, S., & Pivac, N. (2023) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2023.2200937 · Cited by 25
Vasilescu, A.-N., Schweinfurth, N., Borgwardt, S., Gass, P., Lang, U. E., Inta, D., & Eckart, S. (2017) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s119004 · Cited by 21
Schatzberg, A. F. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19030273 · Cited by 21
Yang, P.-S., Peng, H., Lin, T.-B., Hsieh, M., Lai, C., Lee, A., Wang, H.-H., & Ho, Y. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108269 · Cited by 21
Liu, S., Shi, D., Sun, Z., He, Y., Yang, J., & Wang, G. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.601985 · Cited by 19
Viktorov, M., Wilkinson, M. P., Elston, V. C. E., Stone, M., & Robinson, E. S. J. (2022) · Brain and Neuroscience Advances · doi:10.1177/23982128221081645 · Cited by 22
New investigational agents for the treatment of major depressive disorder
Pochwat, B., Krupa, A. J., Siwek, M., & Szewczyk, B. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2113376 · Cited by 22
The Downstaging Concept in Treatment-Resistant Depression: Spotlight on Ketamine
Wilkowska, A., & Cubała, W. J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314605 · Cited by 19
Ribeiro, F. C., Cozachenco, D., Argyrousi, E. K., Staniszewski, A., Wiebe, S. A., Calixtro, J. D., Soares‐Neto, R. L., Al‐Chami, A., Sayegh, F. E., Bermudez, S., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14034 · Cited by 19
Lee, C. J., Chen, Y., Wu, H.-F., Chung, Y.-J., Lee, Y., Li, C., & Lin, H. (2019) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2019.03.015 · Cited by 20
Metadata
- Authors
- Lepack, A. E., Bang, E., Lee, B., Dwyer, J. M., & Duman, R. S.
- Affiliations
- Yale University (US)
- Corresponding author
- Duman, Ronald S.
- Venue
- Neuropharmacology
- Publisher
- Elsevier BV
- Published
- 2016-12
- Volume
- 111
- Pages
- 242-252
- ISSN
- 0028-3908 (ISSN-L)
- PMC
- PMC5075989
- OpenAlex
- W2518741199
- Cited by
- 174
- References
- 42
- Citations by year
- 2026: 7 · 2025: 14 · 2024: 15 · 2023: 20 · 2022: 23 · 2021: 18 · 2020: 20 · 2019: 24 · 2018: 20 · 2017: 13
- FWCI
- 15.38
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Neuropharmacology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- NIMH (R37MH45481, R01MH93897)
- State of Connecticut
- Yale University
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- rapid-acting antidepressants, ketamine, LY341495, ERK signaling, BDNF release, mTORC1, p70 S6 kinase, AMPA receptors, activity-dependent plasticity, neuronal morphology, cortical neurons, muscimol, GABAA receptor
- MeSH terms
- Amino Acids, Animals, Antidepressive Agents, Cells, Cultured, Cerebral Cortex, Dendrites, Ketamine, Oligopeptides, Xanthenes, Receptors, AMPA, Brain-Derived Neurotrophic Factor, Receptor, trkB, MAP Kinase Signaling System, Rats, GABAergic Neurons, Primary Cell Culture
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
